Adynxx, Inc.
ADYX · OTC
Company research
Adynxx, Inc. (OTC: ADYX) is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, focused on the development and commercialization of novel transcription factor decoy technologies for the treatment of pain and inflammatory diseases. Founded in 2007 by Julien Mamet, Ph.D., the company leverages its proprietary AYX platform to create first-in-class, disease-modifying therapeutics that target the molecular roots of pain as an alternative to opioid-based treatments. Its lead pipeline candidate, brivoligide, is currently in Phase II clinical development for the reduction of postoperative pain, while AYX2 remains in pre-clinical development targeting focal chronic pain conditions, including both inflammatory and neuropathic pain. Under the leadership of CEO Rick Orr, Adynxx operates with a lean team of six full-time employees and trades on the OTC markets with a minimal market capitalization.
Research reports
Simply Wall St provides a data-driven fundamental snapshot with zero scores across valuation, growth, performance, financial health, and dividends, highlights illiquidity, negligible market cap, outdated financials, and high risk, and frames ADYX as a highly speculative micro‑cap biotech with limited disclosure and no analyst coverage, rather than offering a clear buy or sell call.
Macroaxis · February 24, 2026Adynxx Inc Stock Market OutlookMacroaxis issues a “Strong Sell” recommendation over a 90‑day horizon, citing deeply negative profitability and liquidity metrics, penny‑stock status, and bearish sentiment, while benchmarking ADYX’s revenue, earnings, leverage, and valuation ratios against much stronger biotech peers to argue that the risk‑reward profile is unfavourable.